Trial Profile
A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With MVA-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in HIV-1 Infected Adults on Suppressive ART
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Ad26 Mos4 HIV (Primary) ; MVA-Mosaic-HIV-vaccine-Janssen-Vaccines-and-Prevention (Primary) ; Aluminium phosphate; HIV clade C gp140 vaccine; HIV mosaic gp140 vaccine
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen Vaccines and Prevention B.V
- 07 Feb 2022 Status changed from active, no longer recruiting to completed.
- 19 Jan 2021 Planned End Date changed from 17 Dec 2021 to 30 Nov 2021.
- 29 Sep 2020 Planned End Date changed from 18 Feb 2022 to 17 Dec 2021.